1. Home
  2. IOVA vs HASI Comparison

IOVA vs HASI Comparison

Compare IOVA & HASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.56

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Logo Hannon Armstrong Sustainable Infrastructure Capital Inc.

HASI

Hannon Armstrong Sustainable Infrastructure Capital Inc.

HOLD

Current Price

$32.70

Market Cap

4.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
HASI
Founded
2007
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
968.6M
4.2B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
IOVA
HASI
Price
$2.56
$32.70
Analyst Decision
Buy
Strong Buy
Analyst Count
12
9
Target Price
$10.45
$39.56
AVG Volume (30 Days)
11.3M
1.1M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
5.15%
EPS Growth
N/A
27.54
EPS
N/A
2.32
Revenue
$250,425,000.00
$99,644,000.00
Revenue This Year
$60.94
$187.33
Revenue Next Year
$60.85
$16.20
P/E Ratio
N/A
$14.07
Revenue Growth
175.62
N/A
52 Week Low
$1.64
$21.98
52 Week High
$8.15
$34.54

Technical Indicators

Market Signals
Indicator
IOVA
HASI
Relative Strength Index (RSI) 58.51 50.59
Support Level $2.08 $32.45
Resistance Level $2.60 $33.17
Average True Range (ATR) 0.14 0.71
MACD 0.02 -0.20
Stochastic Oscillator 77.88 13.32

Price Performance

Historical Comparison
IOVA
HASI

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.

HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.

Share on Social Networks: